Facebook
Instagram
Pinterest
Reddit
Tumblr
X
Youtube
Home
About
News
Events
Shop
Directory
Contact Us
Search
Sign in
Welcome! Log into your account
your username
your password
Forgot your password? Get help
Password recovery
Recover your password
your email
A password will be e-mailed to you.
PsyNews.com
Home
About
News
Events
Shop
Directory
Contact Us
Home
Featured
Page 153
Featured
Latest
Latest
Featured posts
Most popular
7 days popular
By review score
Random
Pα+ Psychedelic Bulletin #225: Q1 Lobbying Update; Individual vs. Group MDMA Therapy Study Launches; Australia Loosens Psychedelics Access Regulations; VA Launches “New” MDMA Trial
Three Brain Injuries, One Iboga Protocol, and What It Tells Us
The War on Drugs Was Never About Drugs. Psychedelic Healing Must Reckon With That.
A Dispatch from APA’s Annual Meeting: Psychedelics Return at an Awkward Moment for American Psychiatry
Momentum Amidst Tumult: The FDA Reshuffle, Approval Timelines, and the Compass-Usona Race
Alberta Puts Patients First By Regulating Psychedelic Therapy: Optimi Health
Silo Pharma to Present at the Dawson James Small Cap Growth...
COMPASS Pathways to Hold Virtual Capital Market Day on 12 October...
MindMed to Participate in the Cantor Fitzgerald Neurology & Psychiatry Conference
Numinus Develops Mushroom Tea for Use in Psychedelic Research
Mindset Pharma Selects Lead Clinical Candidates From “Family 2” of its...
PharmaTher Holdings Announces Grant of U.S. Patent Covering Ketamine for Parkinson’s...
Inflammation Nation: How Psychedelics Could Combat Widespread Chronic Pain
atai Life Sciences Announces First Subject Dosed in Phase 1 Trial...
MindMed Collaborators Initiate Phase 1 Comparative PK/PD Trial of R-, S-...
Load more